Seres Therapeutics, Inc.MCRBNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank23
3Y CAGR-30.7%
5Y CAGR-16.6%
Year-over-Year Change
Research and development spending
3Y CAGR
-30.7%/yr
vs +3.4%/yr prior
5Y CAGR
-16.6%/yr
Recent deceleration
Acceleration
-34.1pp
Decelerating
Percentile
P23
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $36.44M | -43.6% |
| 2024 | $64.60M | -45.1% |
| 2023 | $117.60M | +7.2% |
| 2022 | $109.65M | -22.7% |
| 2021 | $141.89M | +56.7% |
| 2020 | $90.57M | +13.0% |
| 2019 | $80.14M | -16.5% |
| 2018 | $95.95M | +7.3% |
| 2017 | $89.45M | +9.1% |
| 2016 | $81.99M | - |